Change of 9.92% for Regenxbio Inc (NASDAQ:RGNX)’s shares shorted was noted. FINRA issued shares shorted of RGNX’s total 2.66M shares. That’s 9.92% down from 2.95 million shares. Former RGNX’s position will need 6 days to recover. It has 466,600 average volume. Regenxbio Inc float short is 9.56%.
Ticker’s shares touched $56.4 during the last trading session after 3.36% change.Currently REGENXBIO Inc. is uptrending after 185.29% change in last December 6, 2017. RGNX has 319,062 shares volume. RGNX outperformed the S&P500 by 169.67%.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.The firm is valued at $2.02 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.24.55 is the P/E ratio. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.
For more REGENXBIO Inc. (NASDAQ:RGNX) news brought out recently go to: Benzinga.com, Streetinsider.com, Fool.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie – Benzinga” brought out on November 07, 2018, “Regenxbio (RGNX), AveXis (AVXS) Expand Relationship through Amended License Agreement for Development and Commercialization of Treatments for SMA – StreetInsider.com” on January 08, 2018, “Healthcare: 2 Hot Biotech Stocks on Our Radar – The Motley Fool” with a publish date: September 28, 2018, “Benzinga’s Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index – Benzinga” and the last “Premarket analyst action – healthcare – Seeking Alpha” with publication date: March 12, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.